Welcome to our dedicated page for Tivic Health Systems news (Ticker: TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Tivic Health Systems, Inc. (Nasdaq: TIVC) generates news that reflects its evolution into a diversified immunotherapeutics and health technology company. This page aggregates coverage of Tivic’s progress in biologics, bioelectronic medicine and contract development and manufacturing, giving investors and observers a single place to review its latest corporate announcements.
Much of Tivic’s recent news flow centers on Entolimod™, its lead Toll-like Receptor 5 (TLR5) agonist drug candidate for acute radiation syndrome (ARS) and related conditions. Articles highlight milestones such as cell line verification, large-scale manufacturing runs, and steps toward current Good Manufacturing Practice (cGMP) production in preparation for a potential Biologics License Application (BLA). Releases also discuss Entolimod’s Fast Track and Orphan Drug designations, its development under the FDA’s Animal Rule, and animal data showing effects on survival, gastrointestinal recovery and hematopoiesis after radiation exposure.
Another major theme in Tivic news is its acquisition of manufacturing and development assets and the launch of Velocity Bioworks™, a wholly owned CDMO subsidiary. Coverage describes how Velocity Bioworks is expected to support Tivic’s own biologics pipeline and offer development and manufacturing services to third-party biotech companies, creating additional revenue opportunities and reducing reliance on external manufacturers.
Visitors will also find updates on Tivic’s bioelectronic program, including results from a clinical optimization trial of non-invasive cervical vagus nerve stimulation conducted with The Feinstein Institutes for Medical Research at Northwell Health. These stories detail how personalized stimulation parameters can influence autonomic measures such as heart rate variability.
In addition, Tivic regularly reports on its interactions with government and industry stakeholders, including BARDA TechWatch meetings, participation in the Military Health System Research Symposium, and conference presentations outlining its strategic transformation. For investors tracking TIVC, this news feed offers a consolidated view of clinical, manufacturing, partnership and capital markets developments.
Tivic Health (Nasdaq: TIVC), a healthtech company specializing in bioelectronic medicine, was featured in an ABC News story highlighting new bioelectronic technologies for managing conditions like sinus pain and arthritis. ClearUP® Sinus Pain Relief, the only commercially available product showcased, is part of the company's growth strategy following a $17.2 million IPO in November 2021. The company is advancing its Gen2 product and exploring new applications in bioelectronic therapies as alternatives to opioids.
Tivic Health Systems (Nasdaq: TIVC) has launched a 60-person clinical trial to investigate a new bioelectronic device as an alternative to opioids for post-operative care after sinus surgeries. This double-blind study aims to evaluate pain management following functional endoscopic sinus surgery, a common procedure affecting over one million patients annually in the U.S. The company currently offers an FDA-cleared treatment for sinus pain and nasal congestion, seeking to expand its application in pain reduction while minimizing opioid dependence.
Tivic Health Systems, Inc. (NASDAQ: TIVC), a company specializing in non-invasive bioelectronic medicine, has appointed Mindgruve as its digital marketing agency of record. Mindgruve will develop an integrated marketing strategy to enhance brand awareness and optimize e-commerce platforms for Tivic's products, including its FDA-cleared device, ClearUP® Sinus Pain Relief. This partnership aims to capitalize on the growing sinus care market and improve the effectiveness of Tivic's marketing and sales efforts in the U.S.
Tivic Health Systems, Inc. (NASDAQ: TIVC) has received significant recognition as CEO Jennifer Ernst was awarded Inc’s 2021 Female Founders 100 Award. Additionally, the company was listed in Fast Company’s inaugural Next Big Things in Tech 2021 for its FDA-cleared product, ClearUP® Sinus Pain Relief. This innovative device aims to alleviate nasal and sinus inflammation symptoms, marking a key milestone in the bioelectronic medicine sector. Ernst expressed pride in the team’s accomplishments and their mission to enhance healthcare delivery.
Tivic Health Systems, a commercial-phase bioelectronic medicine company, will present at the Sidoti Micro Cap Conference virtually on December 8, 2021, at 3:15 pm ET. CEO Jennifer Ernst will discuss bioelectronic medicine's growth and hold one-on-one investor meetings. Registration for the conference is mandatory, and more details can be found on Sidoti's website. Tivic Health is committed to advancing non-invasive health solutions to enhance wellness and improve lives.
Tivic Health Systems, Inc. (TIVC) announced the closing of its initial public offering, selling 3 million shares at $5.00 each, raising $15 million in gross proceeds. The offering includes a 45-day option for underwriters to purchase an additional 450,000 shares. The proceeds will be used to expand sales of its ClearUP® Sinus Relief device, enhance marketing efforts, and support the launch of ClearUP Gen 2. The company also aims to further clinical research and product development. ThinkEquity acted as the sole book-running manager for the offering.